Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia
Authors' conclusion
The study results identify the clinical characteristics of patients with malignant TIO, permitting the early identification of patients with PMT at increased risk of malignancy. This may significantly improve the diagnostic approach to disease. Further experimental studies are mandatory to clarify the role of FGF23 in the pathogenesis of malignancy in PMTs.
Study context
- Population
- Patients with tumor-induced osteomalacia (TIO) with benign or malignant phosphaturic mesenchymal tumor (PMT) specified; Medline, Google Scholar, Google book and Cochrane Library searched to March 31, 2023
- Participants
- 837 patients
- Comparison
- Malignant vs benign phosphaturic mesenchymal tumor causing TIO
- Malignant PMTn = 89
- Benign PMTn = 748reference
- Outcome
- Clinical characteristics, malignant vs benign PMT
Methodological detailsPRISMA criteria, no language restrictions
- PRISMA criteria
- No language restrictions
Pooled result
As reported in the abstract
- Patients with malignant PMT were younger
- Bone pain, functional impairment and bone deformities more frequent with malignant PMT
- Higher intact FGF23 with malignant PMT
- Higher mortality rate with malignant PMT
Original publication
Clinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia. J Clin Endocrinol Metab. Published 25 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →